The chart uses daily closes adjusted by the available provider. There may be delays, gaps or differences versus the official source.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Compares H1 2025 with H2 2025, summing every instrument of the company each fund holds. A fund switching instrument within the same company doesn't show up here as an entry or exit — for that instrument-by-instrument detail, see the Instruments section.
New positions: 0Exits: 4Increasing exposure: 3Reducing exposure: 2
− ING DIRECT FONDO NARANJA CONSERVADOR, FI
Leaves the position; it weighed 0.01%.
− ING DIRECT FONDO NARANJA DINAMICO, FI
Leaves the position; it weighed 0.03%.
− ING DIRECT FONDO NARANJA MODERADO, FI
Leaves the position; it weighed 0.02%.
− RENTA 4 EEUU ACCIONES, FI
Leaves the position; it weighed 1.01%.
Objective ratios
FCF yield
2.4%
Net debt / EBITDA
-1.78x
P/E
—
52-week range
72.30 – 96.29 USD
Data as-is, not an interpretation: it does not say whether the price is cheap or expensive, and it is not a buy or sell recommendation.
Updated 2026-09-06. Source: Yahoo Finance.
Disclaimer
This is not financial advice. Weights come from the periodic reports each manager files with the CNMV and lag the real close of the period. Price, description and ratios, when available, come from Yahoo Finance and may not exactly match this ISIN if the company has multiple share classes.